Metabolic modulation of tumours with engineered bacteria for immunotherapy.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
10 2021
Historique:
received: 16 05 2019
accepted: 07 09 2021
pubmed: 8 10 2021
medline: 9 2 2022
entrez: 7 10 2021
Statut: ppublish

Résumé

The availability of L-arginine in tumours is a key determinant of an efficient anti-tumour T cell response

Identifiants

pubmed: 34616044
doi: 10.1038/s41586-021-04003-2
pii: 10.1038/s41586-021-04003-2
doi:

Substances chimiques

B7-H1 Antigen 0
Proteome 0
Arginine 94ZLA3W45F

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

662-666

Subventions

Organisme : European Research Council
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Rodriguez, P. C. & Ochoa, A. C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222, 180-191 (2008).
doi: 10.1111/j.1600-065X.2008.00608.x
Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641-654 (2005).
doi: 10.1038/nri1668
Geiger, R. et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829-842.e813 (2016).
doi: 10.1016/j.cell.2016.09.031
Martí i Líndez, A.-A. M. et al. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8
doi: 10.1172/jci.insight.132975
He, X., Lin, H., Yuan, L. & Li, B. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. Cancer Biol. Ther. 18, 94-100 (2017).
doi: 10.1080/15384047.2016.1276136
Spinelli, J. B. et al. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science 358, 941-946 (2017).
doi: 10.1126/science.aam9305
Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785 (2010).
doi: 10.1038/nrc2934
Kitada, T., DiAndreth, B., Teague, B. & Weiss, R. Programming gene and engineered-cell therapies with synthetic biology. Science 359, eaad1067 (2018).
doi: 10.1126/science.aad1067
Zhao, G., Jin, Z., Allewell, N. M., Tuchman, M. & Shi, D. Crystal structure of the N-acetyltransferase domain of human N-acetyl-L-glutamate synthase in complex with N-acetyl-L-glutamate provides insights into its catalytic and regulatory mechanisms. PLoS ONE 8, e70369 (2013).
doi: 10.1371/journal.pone.0070369
Sancho-Vaello, E., Fernandez-Murga, M. L. & Rubio, V. Mechanism of arginine regulation of acetylglutamate synthase, the first enzyme of arginine synthesis. FEBS Lett. 583, 202-206 (2009).
doi: 10.1016/j.febslet.2008.12.001
Rajagopal, B. S., DePonte, J., 3rd, Tuchman, M. & Malamy, M. H. Use of inducible feedback-resistant N-acetylglutamate synthetase (argA) genes for enhanced arginine biosynthesis by genetically engineered Escherichia coli K-12 strains. Appl. Environ. Microbiol. 64, 1805-1811 (1998).
doi: 10.1128/AEM.64.5.1805-1811.1998
Aebersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
doi: 10.1038/nature01511
Malissen, M. et al. Altered T cell development in mice with a targeted mutation of the CD3‐epsilon gene. EMBO J. 14, 4641-4653 (1995).
doi: 10.1002/j.1460-2075.1995.tb00146.x
Kurtz, C. B. et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans. Sci. Transl. Med. 11, aau7975 (2019).
doi: 10.1126/scitranslmed.aau7975
Isabella, V. M. et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857-864 (2018).
doi: 10.1038/nbt.4222
Malissen, M. et al. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J. 14, 4641-4653 (1995).
doi: 10.1002/j.1460-2075.1995.tb00146.x
Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896-1906 (2007).
doi: 10.1038/nprot.2007.261
Scheltema, R. A. et al. The Q Exactive HF, a benchtop mass spectrometer with a pre-filter, high-performance quadrupole and an ultra-high-field Orbitrap analyzer. Mol. Cell. Proteomics 13, 3698-3708 (2014).
doi: 10.1074/mcp.M114.043489
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
doi: 10.1038/nbt.1511
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805 (2011).
doi: 10.1021/pr101065j

Auteurs

Fernando P Canale (FP)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Camilla Basso (C)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Ente Ospedaliero Cantonale, Department of Surgery, Università della Svizzera italiana, Bellinzona, Switzerland.

Gaia Antonini (G)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Michela Perotti (M)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Institute of Microbiology, ETH Zürich, Zürich, Switzerland.

Ning Li (N)

Synlogic, Cambridge, MA, USA.

Anna Sokolovska (A)

Synlogic, Cambridge, MA, USA.

Julia Neumann (J)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Michael J James (MJ)

Synlogic, Cambridge, MA, USA.

Stefania Geiger (S)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.

Wenjie Jin (W)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Institute of Microbiology, ETH Zürich, Zürich, Switzerland.

Jean-Philippe Theurillat (JP)

Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland.

Kip A West (KA)

Synlogic, Cambridge, MA, USA.

Daniel S Leventhal (DS)

Synlogic, Cambridge, MA, USA.

Jose M Lora (JM)

Synlogic, Cambridge, MA, USA.
Intergalactic Therapeutics, Boston, MA, USA.

Federica Sallusto (F)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
Institute of Microbiology, ETH Zürich, Zürich, Switzerland.

Roger Geiger (R)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. roger.geiger@irb.usi.ch.
Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland. roger.geiger@irb.usi.ch.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH